Old Web
English
Sign In
Acemap
>
authorDetail
>
Cameron Helt
Cameron Helt
Eli Lilly and Company
Internal medicine
Medicine
Rheumatoid arthritis
Disease
Concomitant
4
Papers
12
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis.
2020
Arthritis Research & Therapy
Paul Emery
Yoshiya Tanaka
Tracy E. Cardillo
Douglas E. Schlichting
Terence Rooney
Scott D. Beattie
Cameron Helt
Josef S. Smolen
Show All
Source
Cite
Save
Citations (3)
Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
2018
Ronald F. van Vollenhoven
Cameron Helt
Vipin Arora
Jinglin Zhong
Ana Pinto-Correia
Inma de la Torre
David Muram
Show All
Source
Cite
Save
Citations (7)
THU0078 Concomitant use of conventional synthetic dmards and response to baricitinib
2017
Annals of the Rheumatic Diseases
A. Kavanaugh
Cameron Helt
David Muram
Jahangir Alam
Vipin Arora
Al Pinto Correia
I. de la Torre
R. van Vollenhoven
Show All
Source
Cite
Save
Citations (1)
Estimated risk of invasive breast cancer in postmenopausal women with and without family history of the disease.
2011
Menopause
Angelina Sontag
Lawrence Wickerham
Xiao Ni
Beth Mitchell
Cameron Helt
David Muram
Show All
Source
Cite
Save
Citations (1)
1